Business Standard

Cipla gains 3% on USFDA's final approval for Lanreotide injection

ICICI Securities remains positive on Cipla's calibrated approach of focusing more on branded products and core therapies across the world

Cipla, Cipla logo, Cipla headquarters
Premium

SI Reporter Mumbai
Shares of Cipla gained 3% to Rs 887.85 on the BSE in Monday's intra-day trade after the company received the United States Food and Drug Administration's (USFDA) final approval for its Lanreotide injection.

Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL single dose pre-filled syringes. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.

The management said this approval is a significant step for company's US business and is in-line with our aspiration to continue growth in our complex product pipeline and address unmet patient needs.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 20 2021 | 10:23 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com